Four more US biotechs filed to go public Friday as yet more companies clamber to get through a yawning IPO window and onto a market thats signaled its willingness to reward nearly any new drugmaker.
The new entrants are led by ALX Oncology and the biological analytics biotech Berkeley Lights, each of whom filed to raise $100 million. The autoimmune company Pandion Therapeutics also filed for $75 million, and Kiromic Biopharma, a tiny immuno-oncology startup based in San Antonio, filed for $25 million.
These companies will try to capitalize on a 2020 biotech IPO boom that the investment firm Renaissance Capital recently called historic. The spree began in January and, after a brief interlude when the pandemic first hit the US and Europe, has only picked up in the last two months. The 23 companies that have gone public averaged an 80% return on their offering price, according to Renaissance Capital numbers. Every single one priced above their midpoint or upsized their offering.
Unlike most of their fellow newly or would-be public biotechs, Berkeley Lights will enter the market with significant revenue on the books. The company doesnt make drugs but instead has built a digital cell biology platform that can analyze living cells from a variety of different dimensions and, in principal, accelerate drug development. Theyve partnered with Sanofi and Pfizer on antibody discovery and last year, signed a $150 million pact with Ginkgo Bioworks to help the synthetic biology unicorn advance its genetic engineering capabilities.
All told, the company earned $51 million in revenue last year. Unlike a drug developer, they have no cash earmarked for specific pipeline products, and said they will use proceeds for research, potential acquisitions and general corporate purposes.
For ALX Oncology, a successful offering would mean their second $100 million tranche of the year. In February, the California biotech raised $105 million to help advance its sole pipeline candidate: an antibody designed to target CD-47. Thats the same dont-eat-me signal targeted by Irv Weissmans Forty Seven Inc., the biotech Gilead paid $5 billion for in January. ALXs pitch is that their antibodys FC receptor is engineered to not attract macrophages, reducing toxicity. The biotech will use their proceeds to push the drug through its ongoinghead and neck squamous cell carcinomaand gastric cancer trial and begin new trials for it in acute myeloid leukemia and myelodysplastic syndrome. A portion is also earmarked for CMC work.
Founded out of Polaris in 2018, Pandion Therapeutics was tapped last year for an up-to $800 million partnership to help a reorganizing Astellas develop antibodies for auto-immune disorders. That deal included $45 million upfront and the company also earned $80 million from a Series B in April. The new funding will be used to push their lead molecule through Phase I/II trials in ulcerative colitis while also backing preclinical research, particularly on a pair of antibodies meant to turn on the PD-1 checkpoint and tamp down the immune system.
Kiromic, meanwhile, is in part just trying to stay alive. With less than $2 million 5 million when a subsequent $3 million Series B is included in the bank at years end, they acknowledged in their S-1 that theres substantial doubt regarding the Companys ability to continue as a going concern. In this climate, though, thats worked out just fine for other companies. Applied Molecular Transport went publicin May with the same concerns. They ultimately raised $177 million.
View original post here:
The biotech IPO boom is becoming 'historic' as four more throw their hats in - Endpoints News
- First cow to produce human insulin in its milk created in Brazil - Cosmos - March 18th, 2024
- Engineering the Microbiome: CRISPR Leads the Way - The Scientist - March 18th, 2024
- The de-extinction process to bring woolly mammoths back to life - The Week - March 18th, 2024
- CRISPR gene editing applications are expanding dramatically in agriculture. Here are the latest advances - Genetic Literacy Project - March 18th, 2024
- Polymerase Chain Reaction (PCR) - National Human Genome Research Institute - March 18th, 2024
- Colossal Genetic Breakthrough Could Be the Key to Reviving Wooly Mammoths - Syfy - March 18th, 2024
- Breaking: Crop gene editing greenlighted by European Parliament. Fight over labeling looms as measure moves to the ... - Genetic Literacy Project - February 10th, 2024
- GMOs on the spotlight in East Africa again - The Citizen - February 10th, 2024
- Blog: Let's Not Ignore the Science in the Fight Against Malaria - chimpreports.com - February 10th, 2024
- Genetic engineering techniques - Wikipedia - January 9th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - January 9th, 2024
- Genetic Modification Techniques and Applications - Technology Networks - January 9th, 2024
- Transformation-associated recombination (TAR) cloning and its applications - EurekAlert - January 9th, 2024
- Are GMOs Safe? The Benefits of Science-Enhanced Foods | TIME - TIME - January 9th, 2024
- Here's the skinny on fast-emerging genetic engineering tools that are rapidly improving global farming - Genetic Literacy Project - January 9th, 2024
- What Fruit Looked Like 100 Years Ago, Before Genetic Modification - Green Matters - January 9th, 2024
- APHIS Reopens Comment Period on Proposed Additional Exemptions for Plants Modified or Produced Through Genetic Engineering - The National Law Review - January 9th, 2024
- Restriction Enzyme Market is set to Reach US$ 647.41 million at a CAGR of 5.7% from the forecast period 2023 to ... - GlobeNewswire - January 9th, 2024
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - December 13th, 2023
- Star Trek: Julian Bashir's Tale of Genetic Engineering and the Complexity of Parental Acceptance - GameRant - December 13th, 2023
- How to Improve Livestock Health, and Cut - Breakthrough Institute - December 13th, 2023
- Opinion | The Genetically-Engineered Tree That Never Was - Common Dreams - December 13th, 2023
- Genome Editing Market Size and Share to Surpass USD 14.5 billion by 2035 | Roots Analysis - Yahoo Finance - December 13th, 2023
- Dallas-Based Colossal Biosciences Aims to De-Extinct the Woolly Mammoth - The Texan - December 13th, 2023
- Revolutionizing probiotic therapy: The emergence of CRISPR-Cas engineered strains - Medical Xpress - December 13th, 2023
- Genetically engineered cell therapies with mRNA lipid nanoparticles for transferrable platelets - Phys.org - December 13th, 2023
- 'Perhaps GMOs are closer to natural processes than we think': How genetic modification mimics natural evolution of ... - Genetic Literacy Project - December 13th, 2023
- Advancements in Genome Editing and CRISPR-Cas9 Technology - Medriva - December 13th, 2023
- Gene Therapy: Unlocking Innovations in Cancer Treatment, Detection, and Drug Development - Securities.io - December 13th, 2023
- Mayo Clinic Research on Genetically Engineered Virus and CAR-T Cell Therapy for Liver Cancer - Medriva - December 13th, 2023
- Global Gene Editing Market Poised for Significant Growth, Projected to Reach $14.28 Billion by 2027 - EIN News - December 13th, 2023
- Principles of Genetic Engineering - PMC - National Center for ... - May 17th, 2023
- Quitting: A Life Strategy: The Myth of Perseveranceand How the New Science of Giving Up Can Set You Free - Next Big Idea Club Magazine - May 17th, 2023
- 18 Human Genetic Engineering - Clemson University - March 29th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - March 29th, 2023
- How artificial skin is made and its uses, from treating burns to skin cancer - South China Morning Post - March 29th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 13th, 2023
- Revolutionary Specialty Enzymes Transform Industries, Projected to Reach $2.2 Billion by 2031 - Billion-Dollar - EIN News - March 5th, 2023
- Explained: What is genome editing technology and how is it different from GM technology? - The Indian Express - April 2nd, 2022
- Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference - Yahoo... - April 2nd, 2022
- San Antonio Zoo In Discussions on Woolly Mammoth Project - iHeart - April 2nd, 2022
- Xenotransplantation trials will require adjusting expectations, experts say - STAT - April 2nd, 2022
- 5 Interesting Startup Deals You May Have Missed In March: Restoring The Woolly Mammoth, Faux Seafood And Lots Of Bees - Crunchbase News - April 2nd, 2022
- Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for ... - KULR-TV - April 2nd, 2022
- The Bay Area food tech industry is creating more than vegan burgers. Heres whats next - San Francisco Chronicle - April 2nd, 2022
- Student Startup Teams to Compete For $110000 Cash Prize Pool in U of A's Heartland Challenge - University of Arkansas Newswire - April 2nd, 2022
- Should we test for differences in allergen content between varieties of crops and animal species? - Open Access Government - April 2nd, 2022
- Genetic Engineering - Courses, Subjects, Eligibility ... - December 22nd, 2021
- Scientists Used CRISPR Gene Editing to Choose the Sex of Mouse Pups - Singularity Hub - December 22nd, 2021
- Report calls for broad public deliberation on releasing gene-edited species in the wild - EurekAlert - December 22nd, 2021
- RNA and DNA Extraction Kit Market Study | Know the Post-Pandemic Scenario of the Industry - BioSpace - December 22nd, 2021
- Opinion: Allow Golden Rice to save lives - pnas.org - December 22nd, 2021
- It's time for an alliance of democracies | TheHill - The Hill - December 22nd, 2021
- Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19... - December 22nd, 2021
- 2021: when the link between the climate and biodiversity crises became clear - The Guardian - December 22nd, 2021
- Wuhan lab leak now the most likely cause of Covid pandemic and the truth WILL come out, experts tell MPs... - The US Sun - December 22nd, 2021
- Biotech ETFs That Outperformed Last Week - Yahoo Finance - December 22nd, 2021
- Human genetic enhancement - Wikipedia - October 5th, 2021
- Viewpoint: Part 1 Opposition stirred by anti-GMO advocacy group propaganda fading in the developing world, as more countries embrace crop... - October 5th, 2021
- Amyris Partners with Inscripta to Enhance Development of Sustainable Ingredients Using the Onyx Genome Engineering Platform - WWNY - October 5th, 2021
- Kingdom Supercultures raises $25m to expand Non GMO suite of microbes to unlock new flavors, textures, and functionalities in food & beverage -... - October 5th, 2021
- Fact check: Genetically engineering your salad with the COVID-19 vaccines? We're not there yet. - USA TODAY - October 5th, 2021
- Making the Transition from an Academic to a Biobusiness Entrepreneur - Genetic Engineering & Biotechnology News - October 5th, 2021
- Is The New York Times Finally 'Learning To Love GMOS'? - American Council on Science and Health - October 5th, 2021
- Gene editing, joke theft and manifesting - The Week UK - October 5th, 2021
- Opinion: Saving lives through real social justice - Agri-Pulse - October 5th, 2021
- What is biohacking? - News Anyway - October 5th, 2021
- Science, business and the humanities: CP Snow's 'Two Cultures' sixty years on - TheArticle - October 5th, 2021
- Probiotic Yeast Engineered To Produce Beta-Carotene - Technology Networks - April 17th, 2021
- In the US, Imminent Release of Genetically Modified Mosquitoes To Fight Dengue - The Wire Science - April 17th, 2021
- CRISPRoff: A New Addition to the CRISPR Toolbox - Technology Networks - April 17th, 2021
- A Massive New Gene Editing Project Is Out to Crush Alzheimer's - Singularity Hub - April 17th, 2021
- Grammar of the Genome: Reading the Influence of DNA on Disease - Baylor University - April 17th, 2021
- We cannot let China set the standards for 21st century technologies | TheHill - The Hill - April 17th, 2021
- First GMO Mosquitoes to Be Released in the Florida Keys - Singularity Hub - April 17th, 2021
- Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations - BioSpace - April 17th, 2021
- AmunBio and NorthShore University to Advance Cancer Immunotherapy with Engineered Oncolytic Viruses - OncoZine - April 17th, 2021
- StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies - BioSpace - April 17th, 2021
- ThermoGenesis : The History of Cell and Gene Therapy - marketscreener.com - April 17th, 2021
- EU's refusal to permit GMO crops led to millions of tonnes of additional CO2, scientists reveal - Alliance for Science - Alliance for Science - February 14th, 2021